Immunotherapy-combined chemotherapy as first-line treatment for stage IIIB/IV large cell neuroendocrine lung carcinoma.
OBJECTIVES The optimal first-line treatment for advanced large cell neuroendocrine carcinoma of the lung (LCNEC) remains unclear. This study aimed to comprehensively evaluate and compare the efficacy of different first-line treatment regimens in patients with stage IIIB/IV LCNEC. METHODS A retrospective analysis was...